Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan

Mao Chih Hsieh, Chang Yun Lu, Wei Wen Chang, Szu Yuan Wu, Ping Kun Hsiao, Tse Jia Liu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Our hospital was the first institution to offer cytoreduction surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in Taiwan. Therefore, we report our experience and outcomes among patients who underwent HIPEC. Since 2002, 164 eligible patients underwent HIPEC, and we excluded cases of laparoscopic or prophylactic HIPEC. The cases were categorized according to whether they were treated before 2012 (Period 1: 80 cases) or after 2012 (Period 2: 84 cases). The rates of surgical morbidity were 46.3% during Period 1 and 20.2% during Period 2 (P < .01), and the rates of severe complications were 25% during Period 1 and 9.5% during Period 2 (P < .01). The 5-year overall survival rate was 35.8%, with rates of 13.4% for gastric cancer, 27.3% for colon cancer, 70.0% for appendiceal cancer, and 52.4% for ovarian cancer (median follow-up: 34 months). The survival rate was 42.1% when we achieved a cytoreduction score of 0/1, compared with 21.1% in the group with a cytoreduction score of 2/3 (P < .01). Severe complications were associated with a 5-year survival rate of 23.4%, compared with 37.9% among cases without severe complications (P = .01). Complete cytoreduction was achieved in 78.6% of the patients if they underwent their first surgery at our hospital. We have become an experienced hospital for CRS plus HIPEC. Although our complication rate for CRS plus HIPEC was high, it was within the acceptable range. Long-term survival was achieved in a few cases.

Original languageEnglish
Article numbere7306
JournalMedicine (United States)
Volume96
Issue number26
DOIs
Publication statusPublished - Jun 1 2017

Keywords

  • completeness of cytoreduction score
  • cytoreduction surgery
  • early postoperative intraperitoneal chemotherapy (EPIC)
  • hyperthermic intraperitoneal chemotherapy (HIPEC)
  • peritoneal cancer index (PCI)
  • peritoneal carcinomatosis
  • peritonectomy

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Experiences with cytoreduction surgery plus hyperthermic intraperitoneal chemotherapy in Taiwan'. Together they form a unique fingerprint.

  • Cite this